Terminated PHASE3 INTERVENTIONAL 2-arm NCT01526408

Famvir for Treatment of Hearing in Unilateral Meniere's Disease (Famvir)

Treatment of Hearing Fluctuation in Unilateral Meniere's Disease: A Randomized, Placebo-controlled Clinical Trial of Famciclovir

Sponsor: House Clinic, Inc.

Conditions Meniere's Disease

Interventions Famciclovir Placebo

Updated 8 times since 2017 Last updated: Mar 24, 2021 Started: Dec 31, 2011 Primary completion: Jan 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

HRI no longer conducting research.

Other Meniere's Disease trials with similar outcome

Browse all Meniere's Disease trials

Listed as NCT01526408, this PHASE3 trial focuses on Meniere's Disease and remains terminated or withdrawn. Sponsored by House Clinic, Inc., it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE3
May 2021 — Dec 2022 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jan 2021 — May 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

House Clinic, Inc.
House Research Institute

Data source: House Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.